Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- International Price Comparisons for Neurology Drugs
- Overview
- Dementia Therapies
- Parkinson' s Disease Therapies
- Sidebar: Memantine: New Life-and a New Price-for an Old Drug
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- Reformulations and "Me-Too" Drugs
- Reimbursement Environment
- United States
- General Environment
- Private Insurance
- Medicare
- Medicaid
- Sidebar: Patient Assistance Programs-An Important Source of Drug Funding
- Dementia Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- France
- General Environment
- Dementia Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- Germany
- General Environment
- Dementia Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- Italy
- General Environment
- Dementia Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- Spain
- General Environment
- Dementia Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- United Kingdom
- General Environment
- Dementia Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- Japan
- General Environment
- Dementia Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptic Agents
- Outlook and Implications for the Pharmaceutical Industry
- Sidebar: Generic Neurology Drugs-An Increasingly Competitive Market
Tables
- 1. Brand Names and Marketing Companies of Select Neurology Drugs
- 2. Ex-Manufacturer Prices of Select Neurology Drugs in Europe and Japan as
a Percentage of the U.S. Price, 2005
- 3. Average Annual Exchange Rates Against the U.S. Dollar, 2001-2005
- 4. Prices of Reformulations of Dementia Therapies in the United States and
Europe as a Percentage of the Price of the Original Formulations in Each
Market, 2005
- 5. Prices of Dementia Therapies in the United States and Europe as a
Percentage of the Price of Donepezil in Each Market, 2005
- 6. Health Insurance Coverage of the U.S. Population, 2002-2004
- 7. Formulary Positioning of Select Neurology Drugs in Five Leading Managed
Care Organizations
- 8. Formulary Coverage of Select Neurology Drugs in National Medicare
Prescription Drug Plans
- 9. Percentage of State Medicaid Programs Using Various Pharmaceutical
Cost-Containment Measures, 2000, 2003, and 2005
- 10. State Medicaid Programs' Use of Preferred Drug Lists, August 2006
- 11. Status of Select Neurology Drugs in Five States' Preferred Drug Lists
- 12. Assessment of Select Neurology Drugs by France' s Medicines Evaluation
Commission
- 13. Reference and Retail Prices of Select Doses and Pack Sizes of
Neurology Drugs Subject to Reference Pricing in Germany, August 2006
- 14. Out-of-Pocket Payments for Reference-Priced Drugs in Germany
- 15. Patent Expiration Calendar for Select Neurology Drugs
|
Related Report
|
View Cart
